Research programme: immune mobilising mTCR based therapeutics - GlaxoSmithKline/ImmunocoreAlternative Names: ImmTAC based therapeutics - Immunocore
Latest Information Update: 12 Jan 2016
At a glance
- Originator Immunocore
- Developer GlaxoSmithKline; Immunocore
- Class Bispecific antibodies; Immunoproteins; Immunotherapies
- Mechanism of Action Immunomodulators; T-cell receptor antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 09 Jul 2013 Early research in Cancer in United Kingdom (unspecified route)